ALL-PARTY PARLIAMENTARY GROUP FOR ETHNICITY TRANSPLANTATION AND TRANSFUSION

​

The recently formed All-Party Parliamentary Group for Ethnicity Transplantation and Transfusion announced the launch of Parliamentary Inquiry into the access to donors for those from diverse ethnic backgrounds.

​

​

Making chemotherapy kinder for childhood leukaemia

​

In this guest blog post, Dr Rosanna Jackson discusses what scientists are doing to make treatment kinder for children with acute lymphoblastic leukaemia (ALL).

AZ’s new leukaemia drug approved in the US

The FDA has approved a new cancer drug from AstraZeneca, the first medicine to treat a rare and life-threatening form of leukaemia to hit the market for 20 years. 

Biopharma’s acute myeloid leukaemia treatment gains orphan drug designation

​

​

Clinical-stage biopharmaceutical company, ASLAN Pharmaceuticals, has been granted orphan drug designation (ODD) for its treatment for acute myeloid leukaemia (AML) — ASLAN003 — by the US Food and Drug Administration (FDA).

​

New campaign puts spotlight on leukaemia

​

KEIGHLEY people are being urged to learn the symptoms of leukaemia. The plea has been issued by Leukaemia Care to coincide with Blood Cancer Awareness Month.

Drug to treat childhood leukaemia to be made available on the NHS 

A cutting-edge personalised treatment for a form of childhood leukaemia is to be made available on the NHS in the first deal of its kind in Europe.

We can all help control the virus if we all stay alert. This means you must:

• stay at home as much as possible

• work from home if you can

• limit contact with other people

• keep your distance if you go out (2 metres apart where possible)

• wash your hands regularly

Do not leave home if you or anyone in your household has symptoms.

Jazz Pharma’s leukaemia drug wins EU approval for AML

​

The European Commission has approved Jazz Pharmaceuticals' Vyxeos for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia or AML with myelodysplasia-related changes. 

Kymriah approved for acute lymphoblastic leukaemia

​

Novartis has announced that the European Commission (EC) has approved Kymriah® for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL).